EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance

Sonia Mazumder iD, Paul J Higgins, Rohan Samarakoon

Cancers · 19.02.2023 · 15 (4) · 1316

DOI: 10.3390/cancers15041316 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.02.2023. Verfasst von Sonia Mazumder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative & Cancer Cell Biology, Albany Medical College, Albany, NY 12208, USA. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH, Friedman Family Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clear cell variant of renal cell carcinoma (ccRCC) is the most common renal epithelial malignancy and responsible for most of the deaths from kidney cancer. Patients carrying inactivating mutations in the Von Hippel-Lindau (VHL) gene have an increased proclivity to develop several types of tumors including ccRCC. Normally, the Hypoxia Inducible Factor alpha (HIF-α) subunits of the HIF heterodimeric transcription factor complex are regulated by oxygen-dependent prolyl-hydroxylation, VHL-mediated ubiquitination and proteasomal degradation. Loss of pVHL function results in elevated levels of HIF-α due to increased stability, leading to RCC progression. While HIF-1α acts as a tumor suppressor, HIF-2α promotes oncogenic potential by driving tumor progression and metastasis through activation of hypoxia-sensitive signaling pathways and overexpression of HIF-2α target genes. One strategy to suppress ccRCC aggressiveness is directed at inhibition of HIF-2α and the associated molecular pathways leading to cell proliferation, angiogenesis, and metastasis. Indeed, clinical and pre-clinical data demonstrated the effectiveness of HIF-2α targeted therapy in attenuating ccRCC progression. This review focuses on the signaling pathways and the involved genes (cyclin D, c-Myc, VEGF-a, EGFR, TGF-α, GLUT-1) that confer oncogenic potential downstream of the VHL-HIF-2α signaling axis in ccRCC. Discussed as well are current treatment options (including receptor tyrosine kinase inhibitors such as sunitinib), the medical challenges (high prevalence of metastasis at the time of diagnosis, refractory nature of advanced disease to current treatment options), scientific challenges and future directions.

Schlagwörter

Stichwörter der Autor:innen

EGFRHIF-αMETVHLccRCC

Autor:innen und Institutionen

  • Department of Regenerative & Cancer Cell Biology, Albany Medical College, Albany, NY 12208, USA.

ORCID-Profile: Sonia Mazumder

Förderung

  • NIH HHS
  • NIH
  • Friedman Family Research Fund
  • Charlotte Graver Foundation
  • John Faunce and Alicia Tracy Roach Fund
  • Edith Dickstein and Sylvan Kessler Estate Foundation
  • Butler Family Mesothelioma Research Fund
  • Mueller Family Cancer Foundations (PJH)

Zitieren

APA

Mazumder, S., Higgins, P. J., & Samarakoon, R. (2023). Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers, 15(4), 1316. https://doi.org/10.3390/cancers15041316

Vancouver

Mazumder S, Higgins PJ, Samarakoon R. Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers. 2023;15(4):1316. doi:10.3390/cancers15041316

BibTeX
@article{Mazumder2023,
  author = {Mazumder, Sonia and Higgins, Paul J and Samarakoon, Rohan},
  title = {Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1316},
  doi = {10.3390/cancers15041316}
}
Kostenlos starten →